A Phase 3 interventional study of Anakinra and Placebo in Still's Disease, Juvenile Onset and Still's Disease, Adult-Onset, sponsored by Swedish Orphan Biovitrum. Active, not recruiting at 8 sites in Japan. Open to participants aged 8 Months and older. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2022, is one of 10 in phase 3, and was the 11th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.
Browse Arthritis, Juvenile studies →3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Japan, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Japan, United States, Argentina and 14 more countries
Ages 1–17
Eli Lilly and Company · Sites in Japan, Argentina, Australia and 17 more countries
Ages 1–18
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 68 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 49 (72%) stop at 75 or younger; 64 take children under 18; 11 take healthy volunteers.
This study: 8 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 58 across the 11 interventional studies, 113 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
Swedish Orphan Biovitrum is the lead sponsor of 82 studies on the registry; 6 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Swedish Orphan Biovitrum has 9 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]).
The study consists of two phases:
At the Week 54 visit, patients who consent and are eligible to continue anakinra treatment, will enter the extension phase and continue open label anakinra treatment.
The primary endpoint will be evaluated at Week 2 visit.
Key Inclusion Criteria:
Key Exclusion Criteria:
Use of the following therapies prior to enrollment.
After completion of the study Core Phase, patients who consent and are eligible to continue anakinra treatment, can enter the extension phase .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 mg/day or 2 mg/kg/day of subcutaneous anakinra for those with a body weight ≥50 kg or \<50 kg, respectively.
Drug: Anakinra
Corresponding volume to 100 mg/day or 2 mg/kg/day
Drug: Placebo
sub cutaneous daily injection
Also known as: Kineret
sub cutaneous daily injection
An improvement of ≥ 30% from baseline in physician global assessment of disease activity (visual analogue scale [VAS]).
ACR30 response with absence of fever attributable to the disease during the 7 days
Time frame: Week 2
An improvement of ≥ 30% from baseline in patient/parent global assessment of overall well-being (VAS).
ACR30 response with absence of fever attributable to the disease during the 7 days
Time frame: Week 2
An improvement of ≥ 30% from baseline in number of joints with active arthritis.
ACR30 response with absence of fever attributable to the disease during the 7 days
Time frame: Week 2
An improvement of ≥ 30% from baseline in number of joints with limitation of motion.
ACR30 response with absence of fever attributable to the disease during the 7 days
Time frame: Week 2
An improvement of ≥ 30% from baseline in assessment of physical function: Child health assessment questionnaire (CHAQ)/Stanford health assessment questionnaire (SHAQ).
ACR30 response with absence of fever attributable to the disease during the 7 days
Time frame: Week 2
An improvement of ≥ 30% from baseline in C-reactive protein (CRP) (mg/L).
ACR30 response with absence of fever attributable to the disease during the 7 days
Time frame: Week 2
Change in CRP.
To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.
Time frame: Week 2
Change in ferritin.
To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.
Time frame: Week 2
Change in haemoglobin.
To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.
Time frame: Week 2
Change in platelets count.
To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.
Time frame: Week 2
Change in white blood cells count.
To demonstrate the efficacy of anakinra compared to placebo in reducing inflammation in Still's disease.
Time frame: Week 2
Absence of fever during the 24 hours preceding the evaluation visit at Week 1.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Absence of rash during the 24 hours preceding the evaluation visit at Week 1.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
ACR30 response with absence of fever during the 24 hours preceding the evaluation visit at Week 1.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
ACR50 response with absence of fever during the 24 hours preceding the evaluation visit at Week 1.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
ACR70 response with absence of fever during the 24 hours preceding the evaluation visit at Week 1.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in physician global assessment of disease activity, measured on a VAS from no pain (0 mm) to very severe (100 mm).
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in patient/parent global assessment of overall well-being, measured on a VAS from no pain (0 mm) to very severe (100 mm).
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in patient/parent global assessment of disease related pain, measured on a VAS from no pain (0 mm) to very severe (100 mm).
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in swelling joints count.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in tender joints count.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in CRP.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in ferritin.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in haemoglobin.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in platelets count.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in white blood cells count.
To demonstrate early onset of efficacy of anakinra compared to placebo in Still's disease.
Time frame: Week 1
Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y Proxy (4-7 years).
To evaluate and compare the health status between anakinra treated patients and patients treated with placebo.
Time frame: Week 2
Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y (8-15 years).
To evaluate and compare the health status between anakinra treated patients and patients treated with placebo.
Time frame: Week 2
Change in the number/proportion of patients reporting problems by dimension of EQ-5D-3L (≥ 16 years).
To evaluate and compare the health status between anakinra treated patients and patients treated with placebo.
Time frame: Week 2
Absence of fever during the 7 days preceding the visit.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Absence of rash during the 7 days preceding the visit.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
ACR30 response with absence of fever during the 7 days preceding the visit.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
ACR50 response with absence of fever during the 7 days preceding the visit.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
ACR70 response with absence of fever during the 7 days preceding the visit.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
ACR90 response with absence of fever during the 7 days preceding the visit.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in physician global assessment of disease activity (VAS).
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in patient/parent global assessment of overall well-being (VAS).
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in patient/parent global assessment of disease related pain (VAS).
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in swelling joints count.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in tender joints count.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in CRP.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in ferritin.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in haemoglobin.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in platelets count.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Change in white blood cells count.
To evaluate efficacy of anakinra in Still's disease.
Time frame: Week 4 to Week 54
Occurrence of inactive disease.
Proportion of patients who reach inactive disease.Inactive disease is defined as no joints with active arthritis, no fever, no rash, serositis, no hepatosplenomegaly, no generalized lymphadenopathy attributable to Still's disease, CRP level within normal limits, physician's global assessment of disease activity score below 10 mm on a 100 mm VAS, and a documented morning stiffness ≤15 min.
Time frame: Week 8 to Week 54
Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y Proxy (4-7 years).
To evaluate the health status in anakinra treated patients with Still's disease.
Time frame: Week 4 to Week 54
Change in the number/proportion of patients reporting problems by dimension of EQ-5D-Y (8-15 years).
To evaluate the health status in anakinra treated patients with Still's disease.
Time frame: Week 4 to Week 54
Change in the number/proportion of patients reporting problems by dimension of EQ-5D-3L(≥ 16 years).
To evaluate the health status in anakinra treated patients with Still's disease.
Time frame: Week 4 to Week 54
ACR30 response with absence of fever during the 7 days preceding the study visits over time.
To evaluate sustained efficacy of anakinra in patients responding to study drug.
Time frame: Week 2 to Week 54
To evaluate the occurrence of study drug discontinuation in anakinra treated patients with Still's disease.
* Time to study drug discontinuation due to lack of efficacy or progressive disease. * Time to study drug discontinuation due to any reason. * Number of patients discontinuing study treatment.
Time frame: Day 1 to Week 54
Time of initiation of glucocorticoids tapering.
To evaluate glucocorticoids tapering in anakinra treated patients with Still's disease.
Time frame: Week 2 to Week 54
Percentage decrease of glucocorticoids dose for patients tapering their glucocorticoids dose.
To evaluate glucocorticoids tapering in anakinra treated patients with Still's disease.
Time frame: Week 2 to Week 54
Discontinuation of glucocorticoids.
To evaluate glucocorticoids tapering in anakinra treated patients with Still's disease.
Time frame: Week 2 to Week 54
- Occurrence of adverse events (AEs) (serious adverse events [SAEs] and non-SAEs).
To evaluate the safety of anakinra in patients with Still ́s disease.
Time frame: Baseline to Week 58
Occurrence of deaths
To evaluate the safety of anakinra in patients with Still ́s disease.
Time frame: Baseline to Week 58
Occurrence of AEs leading to study drug discontinuation at all study visits.
To evaluate the safety of anakinra in patients with Still ́s disease.
Time frame: Baseline to Week 58
Occurrence of vital signs changes from baseline, including blood pressure, heart rate, and body weight at all study visits up to Week 58 visit. Changes of height in patients younger than 19 years old.
To evaluate the safety of anakinra in patients with Still ́s disease.
Time frame: Baseline to Week 58
Occurrence of laboratory safety assessments changes over time.
To evaluate the safety of anakinra in patients with Still ́s disease.
Time frame: Baseline to Week 58
Occurrence of abnormal laboratory values.
To evaluate the safety of anakinra in patients with Still ́s disease.
Time frame: Baseline to Week 58
To evaluate immunogenicity of anakinra in patients with Still's disease.
* Occurrence of ADAs, NAbs, cross-reactivity, and titer levels of ADAs and NAbs * Occurrence and titer levels of ADAs in relation to AEs * Occurrence and titer levels of ADAs, NAbs cross-reactivityin relation to ACR30 response and CRP levels
Time frame: Baseline, Weeks 2, 4, 12, 34, 54 and 58
To evaluate the pharmacokinetic of anakinra in patients with Still's disease
Anakinra serum concentrations
Time frame: Baseline, Weeks 1 and 2
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Dec 2025, 39 months after the start.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's planned 39 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interleukin 1 Receptor Antagonist Protein